Navigation Links
Meridian Clinical Research is a Finalist for Two Vaccine Industry Excellence Awards, Expects Elevated Demand for Vaccine Trials in 2020

Meridian Clinical Research, a leading investigative research network, is a finalist to win the 2020 Vaccine Industry Excellence (ViE) award for Best Clinical Trial Site. Meridian is also the largest member of Platinum Research Network, which is a finalist for the Best Clinical Trial Network award. These nominations were the result of two voting rounds, and winners will be announced at the World Vaccine Congress in Washington, D.C. in early April.

The nomination comes as Meridian has experienced its largest ever year for vaccine and infectious disease study enrollment. “We’re the partner of choice for many high-volume and specialized vaccine trials,” said Nicole Osborn, CEO. “2020 will be a crucial year for novel vaccine development. We’ve expanded our network, reinforced our in-house quality programs, and scaled up our processes to prepare for significant demand.”

As of mid-February, the CDC reported that influenza activity is still widespread in 47 states. The coronavirus (COVID-19) outbreak is also drawing greater attention in the U.S.

Meridian conducted clinical trials for Zika virus and anthrax vaccines in the past year. In 2015, Meridian also ran a Phase I study for the Ebola vaccine when the outbreak affected the Democratic Republic of Congo. Osborn said the spread of Zika and Ebola spurred many to ask Meridian about clinical trials.

“Our current patients and people naive to research are asking about coronavirus and the vaccine development process,” said Osborn. “Whenever there’s an outbreak, it gives healthcare providers an opportunity to educate people about the importance of clinical research. We encourage people to call us or talk to their doctors to learn more about the process.”

People interested in current studies and the research process can contact a Meridian call center — (402) 934-7563 in the Midwest and (912) 623-2240 for the South and East Coast.

To learn more about Meridian’s vaccine experience, visit To view current study and career opportunities at its locations across the U.S., visit


Meridian Clinical Research partners with pharmaceutical and biotechnology companies to research new pharmaceutical drugs, medical devices, and diagnostics that could improve human health and wellbeing. Founded in 1999, Meridian is headquartered at a dedicated research center in Omaha, NE, and conducts Phase I-IV studies at investigative sites across North America. Meridian supports research across numerous therapeutic areas and specializes in high-volume vaccine trials. For more information, visit

Read the full story at

Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved

Related biology news :

1. Mitotech and Essex Bio-Technology Announce Enrollment in VISTA-2 – a pivotal Phase 3 Clinical Study of SkQ1 for Dry Eye Disease
2. Roswell Park Spinoff Company Advances Toward New Clinical Trial for Brain Cancer Immunotherapy SurVaxM
3. Personalized Stem Cells, Inc. Announces First Patients Treated in FDA Approved Clinical Trial for Treatment of Osteoarthritis with Stem Cells
4. StageBio and Alizée Pathology join forces to meet the growing demand for high-quality histopathology and medical device services in the preclinical services market
5. Former Vice President and Global Head of Quantitative Clinical Pharmacology at AstraZeneca Joins NDA Partners
6. Advanced Clinical Expands Global Reach with New Romania Offices
7. Advanced Clinical Appoints Dr. Pavel Tyan to Lead and Enhance Therapeutic Oncology Research
8. Personalized Stem Cells, Inc. Announces First Patients Enrolled in FDA Approved Clinical Trial for Treatment of Osteoarthritis with Stem Cells
9. VISTAAR Announces Addition of “ADVISORY Playbooks” to it’s Regulatory & Clinical Intelligence Platform
10. Best Practices for EEG Analyses in Nonclinical Seizure Liability Studies, Upcoming Webinar Hosted by Xtalks
11. Capturing the Value of Clinical Trial Intelligence, New Webinar Hosted by Xtalks
Post Your Comments:
(Date:4/23/2020)... FRANKLIN, Wis. (PRWEB) , ... April 23, 2020 ... ... with its expansion and recruitment plans. MDG provides critical infrastructure products for the ... to push MDG’s previous plans for expansion. Further, as supply channels from overseas ...
(Date:4/22/2020)... ... April 21, 2020 , ... Captis ... venture capital firm that provides patent development support for early stage startups. The ... illnesses such as ovarian cancer and precancerous pancreatic lesions with simple, accurate and ...
(Date:4/22/2020)... ... ... Worcester Polytechnic Institute (WPI) is expanding an existing science and engineering training ... spike of COVID-19 cases. As part of its longtime Math and Science for Sub ... materials to be sent to six countries to facilitate the manufacturing of masks, face ...
Breaking Biology News(10 mins):
(Date:5/21/2020)... , ... May 20, 2020 , ... ... of Simon Prakash, who will serve as the company’s executive vice president of ... time when Exo is disrupting the medical imaging space, bringing more than 24 ...
(Date:5/15/2020)... ... ... Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell ... will continue to lead Sentien’s Board of Directors, a role he has filled for ... Sentien’s management team. , Mr. Ganz has more than 30 years of ...
(Date:5/14/2020)... TORONTO (PRWEB) , ... May 13, 2020 , ... ... simple reporter assays or phenotypic readouts, providing little or no information on the ... enable a more comprehensive characterization of compounds by measuring the activity of molecular ...
(Date:5/5/2020)... TAMPA, Fla. (PRWEB) , ... May 05, 2020 ... ... technology and solutions company, announced today the launch of its iGlucose® ... The new iGlucose solution utilizes LTE Cat-M1 technology, the industry’s newest and broadest ...
Breaking Biology Technology: